Relay Therapeutics, Inc.
A clinical-stage biotechnology company in Cambridge, Massachusetts, that designs small-molecule medicines by studying how proteins move and change shape, using its Dynamo platform to create "movies" of protein motion rather than static snapshots. Founded in 2015 as Allostery, Inc., it was renamed Relay Therapeutics to reflect that focus on protein motion, and its lead drug candidate targets a common mutation in breast cancer.
Sold 6.00M
Sold 5.62M
Granted 1.53M · Bought 25.0K · Sold 1.34M
Bought 25.0K · Sold 25.0K
Granted 1.03M · Sold 633.5K
Granted 511.4K · Bought 10.0K · Sold 149.9K
Granted 608.4K · Sold 345.3K
Granted 796.2K · Sold 569.9K
Granted 42.2K · Bought 25.0K
Granted 24.2K · Sold 2.4K
Bought 25.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| SB Investment Advisers (Uk) LTD +2 co-filers10% owner · 2 transactions | — | 21.90M | — | — | 6.00M |
| Levin Mark J +8 co-filers10% owner · 12 transactions | — | 21.67Mas of Jan 2021 | — | — | 5.62M |
| Shaw David E +1 co-filer10% owner · 1 transaction | — | 3.28Mas of Jul 2020 | — | — | — |
| Patel SanjivPresident and CEO, Director · 69 transactions | — | 3.00M | 1.53M | 25.0K | 1.34M |
| Murcko MarkDirector · 4 transactions | — | 997.0Kas of Sep 2022 | — | 25.0K | 25.0K |
| Alexandria Venture Investments, LLC10% owner · 1 transaction | — | 968.4Kas of Jul 2020 | — | — | — |
| Bergstrom Donald APresident, R&D · 82 transactions | — | 512.0K | 1.03M | — | 633.5K |
| Adams BrianChief Legal Officer · 51 transactions | — | 371.5Kas of Jul 2025 | 511.4K | 10.0K | 149.9K |
| Rahmer PeterSee remarks · 46 transactions | — | 275.9K | 608.4K | — | 345.3K |
| Borisy AlexisDirector · 4 transactions | — | 234.2Kas of Mar 2021 | — | — | — |
| Catinazzo ThomasChief Financial Officer · 77 transactions | — | 177.5K | 796.2K | — | 569.9K |
| Rubin JamiDirector · 2 transactions | — | 67.2Kas of Jun 2024 | 42.2K | 25.0K | — |
| Porter AndyChief Administrative Officer · 8 transactions | — | 45.2Kas of Oct 2022 | 24.2K | — | 2.4K |
| Shawver LauraDirector · 1 transaction | — | 40.0Kas of May 2023 | — | — | — |
| Ingram Douglas SDirector · 1 transaction | — | 25.0Kas of Jul 2020 | — | 25.0K | — |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over all recorded history: -14.58M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.